February 27, 2021, the Food and Drug Administration issued an EUA for the third vaccine for the prevention of COVID–19. The EUA allowed the Janssen COVID–19 vaccine to be distributed in the United States for use in individuals 18 years of age and older. (28) On July 13, 2022, the Food and Drug Administration issued an EUA for the fourth vaccine for the prevention of COVID–19 in individuals 18 and older. The EUA was further expanded to include individuals 12 years of age and older. The EUA allowed the Novavax COVID–19 Vaccine, Adjuvanted to be distributed in the United States for use in individuals 12 years and older. (29) On August 23, 2021, the Food and Drug Administration approved the first COVID–19 vaccine, Pfizer-BioNTech’s Comirnaty (COVID–19 vaccine, mRNA) for individuals 16 years of age and older. (30) On January 31, 2022, the Food and Drug Administration approved the second COVID–19 vaccine. The Moderna COVID–19 vaccine Spikevax is approved for individuals 18 years of age and older. (31) Because of this public-private partnership and the funding and support from Congress, multiple COVID–19 vaccines have been developed and manufactured and as of January 19, 2023, approximately 667,815,331 vaccine doses had been administered in the United States. (32) Despite the successful development, rollout, and uptake of the COVID–19 vaccines, it is now known that the vaccines do not fully prevent infection from the SARS–CoV–2 virus. (33) The emergence of variants of SARS–CoV–2 has resulted in the development of new COVID–19 vaccines and booster shots. (34) According to the Food and Drug Administration fact sheets on COVID–19 vaccines, there are certain populations for whom existing COVID–19 vaccines are not indicated or authorized or for whom there is insufficient data to inform vaccine-related risks including— (A) people who have had a severe allergic reaction to a previous dose of one of the vaccines or has a severe allergy to any of the vaccine components